• +1 (732) 369 9777
  • +1 (609) 857 6083
  • enquiry@dimensionmarketresearch.com

logo Antisense and RNAi Therapeutics Market

Comprehensive Industry Landscape and Strategic Outlook

  • About Us
  • Insight
    Trending Reports Latest Reports
  • Industries
    Aerospace & Defence
    Agriculture & Horticulture
    Automotive
    BFSI & Education
    Chemical & Material
    Consumer Goods
    Electrical & Semiconductor
    ICT & TMT
    Energy & Power
    Food & Beverages
    Industry Automation & Equipment
    Manufacturing & Construction
    Medical Devices & Healthcare IT
    Metals & Minerals
    Packaging & Logistics
    Pharmaceuticals & Healthcare
    Sports & Fitness
  • News And Media
  • Contact us
Speak to Analyst
Request Free Sample
/images/logo.png
  • home
  • Pharmaceuticals & Healthcare
  • Antisense and RNAi Therapeutics Market

Antisense and RNAi Therapeutics Market By Technology (RNA Interference & Antisense RNA), By Route of Administration, By Application - Global Industry Outlook, Key Companies (GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals and others), Trends and Forecast 2024-2033

Published on : March-2024  Report Code : RC-793  Pages Count : 251  Report Format : PDF
Overview Table of Content Download Report's Excerpt Request Free Sample

Market Overview

The Global Antisense and RNAi Therapeutics Market is expected to be valued USD 5.5 billion in 2024 and is anticipated to reach USD 27.2 billion by 2033 at a CAGR of 19.4%.  

Antisense and RNAi therapeutics experienced robust growth during 2023, driven by advances in genetic disorders treatment. Multiple RNAi therapies targeting rare conditions like Alport syndrome and Huntington's disease entered clinical trials as milestones in precision medicine and genetic therapies.

FDA's recent approval of RNA interference (RNAi) treatments for liver diseases has given market momentum an additional boost. In April 2023, they granted approval of an innovative RNAi drug designed to treat familial amyloid polyneuropathy (FAP), underscoring RNAi technologies' expansive potential in neurological conditions and liver-related ailments.

Antisense and RNAi Therapeutics Market Growth Analysis

Antisense and RNA interference therapies share the common goal of controlling gene expression to treat genetic disorders. Synthetic short DNA or RNA molecules that enhance particular RNA sequences within cells are attached to their target RNA and form a double-stranded structure that prevents the target RNA from functioning normally. 

Antisense therapy shows the ability to treat many diseases by modifying gene expression, including cancer, genetic disorders, and viral infections, while RNA interference naturally regulates genes within cells.

By investing more into genetic research, companies are turning their attention towards new RNAi-based therapies designed to combat cancer, cardiovascular diseases, and autoimmune disorders. Strategic partnerships between biopharma companies and academic institutions create additional opportunities for RNA-targeted treatments - fuelling further market expansion.

In terms of regional distribution, North America holds the largest market share at 48%, largely due to advancements in RNAi drug development and FDA approvals. The European market follows with 30%, while the Asia-Pacific region has seen 12% growth in RNAi therapeutic research, especially in China and India, where demand is increasing for innovative treatments.

Genetic therapies present great growth prospects for rare diseases and chronic conditions. Prosperous research efforts into RNA interference and antisense technologies for oncology and metabolic conditions could open new treatment avenues in coming years, representing substantial growth opportunities in this market segment.

Key Takeaways

  • At USD 5.5 billion in 2024, the global antisense and RNAi therapeutics market is predicted to grow and is projected to rise at a CAGR of 19.4% to USD 27.2 billion by 2033.
  • The antisense RNA segment is expected to hold the largest market share based on technology in 2024.
  • The intrathecal injections segment is expected to dominate the market in terms of route of administration with a share of 44.3% in 2024.
  • The neurodegenerative disorders sector is expected to dominate the market with a 60.1% revenue share in 2024.
  • North America is expected to lead the market with a 66.2% share of the global market in 2024.

Use Cases

  • Antisense and RNAi therapies have shown the ability to target specific genes involved in cancer development and progression as these can obstruct cancer cell growth and induce programmed cell death by preventing the expression of oncogenes or genes critical for tumor survival.
  • These therapies are used for treating neurological disorders by changing the expression of disease-causing genes as antisense oligonucleotides can target and reduce the expression of the mutant huntingtin protein responsible for neuronal toxicity.
  • These methods can stop viruses from multiplying by aiming at important viral genes or control regions.
  • These treatments are used in managing metabolic disorders by adjusting the activity of genes related to metabolic processes, such as targeting genes linked to cholesterol or glucose metabolism to address conditions like high cholesterol or diabetes.

Market Dynamic

In various medical disorders, whether they are genetic or hereditary, antisense technology is efficient in gene expression transformation which identifies the targeted sequence. The market is expanding due to the adoption of 3D printing technologies in their products. Antisense oligonucleotide and RNAi therapies are two different therapeutic ways that use oligonucleotides to deal with rare diseases and they have shown better therapeutic outcomes at the same time. Another factor is that there are particular no treatment options for rare diseases on the global level.

As a result, there is a progressive rise in financing and research initiatives aimed at creating innovative treatments for rare diseases. Also, major progress made by key players in the development of siRNA-based therapies for several diseases is anticipated to fuel the industry's expansion in the upcoming years. Furthermore, many studies have explored antisense and RNAi therapy as promising treatments for COVID-19. These papers and studies support scientists working on RNA interference and antisense technology which is expected to fuel the market expansion. However, the higher cost of RNA interference-based drugs hampering the growth of this market.

Research Scope and Analysis

By Technology

The antisense RNA segment is expected to hold the largest market share based on technology in 2024, primarily due to its revenue generation dominance and common testing for controlling many conditions. Further, this technology regulates both protein and gene expression, finding applications in cardiovascular, respiratory, neurodegenerative, and genetic disorders, expected to fuel segment growth.

Studies show the potential of antisense oligonucleotide therapies in treating various disorders, including infectious diseases, further increasing the demand for antisense RNA technology. Furthermore, the RNA interference technology segment is anticipated to witness a higher CAGR over the forecast period. 

This technology is used to investigate gene functions in model organisms and cell cultures, and it is also used to target specific gene sequences associated with cancer. Moreover, this technology finds its application in treating bacterial diseases, viruses, and parasites, as well as providing pain relief.

By Route of Administration

The intrathecal injections segment is expected to dominate the market with a share of 44.3% in 2024. It is a method of delivering medicines that involves injecting them into the spinal canal or subarachnoid space to reach the cerebral spinal fluid. 

This method is applied in pain management, spinal anesthetic, chemotherapy, and the introduction of medications to fight particular infections, particularly following neurosurgery procedures. Also, every genetically modified molecule is to consider the route of medication delivery as one of its most important components.

Furthermore, the subcutaneous segment is anticipated to witness the highest CAGR over the forecast period as this injection is delivered in fatty tissue directly beneath the epidermis. The infusion site can be freely chosen with this kind of delivery, possible locations include the thighs, belly, and backs of the arms. This facilitates smaller needle sizes, potentially reducing discomfort during the infusion process.

By Application

The neurodegenerative disorders sector is expected to dominate the market with a 60.1% revenue share in 2024, acting industry player to enhance RNAi and antisense therapies for treating such conditions. Government efforts, along with initiatives by other major firms, are anticipated to drive growth in this segment. Besides that, the genetic disorders segment shows the highest CAGR in 2024 among the others since the amount of investigation devoted to nucleotide drugs is growing very fast.

One more scenario, where mutations in some genetic disorders promote abnormal splicing of pre-mRNA is essential for the formation of diseased or not at all functional proteins. Controlling a normal splicing process by using antisense and RNAi tools gives rise to correct mRNA processing, thereby leading to the abrogation of mutated proteins.

Antisense and RNAi Therapeutics Market Growth Analysis

The Antisense and RNAi Therapeutics Market Report is segmented based on the following

By Technology

  • RNA Interference
  • Antisense RNA

By Route of Administration

  • Intrathecal Injections
  • Intravenous Injections
  • Subcutaneous Injections
  • Others

By Application

  • Neurodegenerative Disorders
  • Genetic Disease
  • Cancer
  • Infectious Disease
  • Cardiometabolic & Renal Disorders
  • Others

Regional Analysis

North America is expected to lead the market with a 66.2% share of the global market in 2024, due to several RNAi treatments being developed in this region. Moreover, many biopharma companies have spent heavy amounts of capital developing therapeutic RNAi treatments. Several sectors that help these sectors work in the region are being developed, the big companies in healthcare and pharmaceuticals being the major players in the area. 

This market has seen significant gains as the technologies that use RNA have improved and they have shown effective results in different fields. Europe; in second position, is projected to be a fast-developing area within the market. There are companies in Europe that are working on antisense and RNAi therapeutics, higher the regional market growth for the predicted period.

Antisense and RNAi Therapeutics Market Growth Analysis

North America
  • The U.S.
  • Canada
Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Russia
  • Spain
  • Benelux
  • Nordic
  • Rest of Europe
Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • ANZ
  • ASEAN
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Egypt
  • Rest of MEA

Competitive Landscape

The key players in this market are looking to progress in these therapies for the treatment of many conditions as antisense oligonucleotide therapies show significance in addressing several disorders, such as infectious diseases. Major players in the market are engaging in strategic actions like partnerships, launching new products, and acquisitions to enhance their market standing and expand their market positioning. Businesses are introducing innovative treatments to diversify their product portfolios and extend their market reach.
 
Some of the key players in the global antisense and RNAi therapeutics market are:
  • GSK plc
  • Olix Pharmaceuticals, Inc.
  • Sanofi
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma
  • Benitec Biopharma Inc.
  • Silence Therapeutics
  • Ionis Pharmaceuticals, Inc
  • Sarepta Therapeutics
  • Percheron Therapeutics Limited
  • Others

Recent Development

  • In August 2023, Sirnaomics Ltd completed phase I clinical trials for STP707, an RNAi therapy targeting multiple solid tumors.
  • In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche to develop and commercialize zilebesiran, an RNAi therapy for hypertension.
  • In July 2023, Ionis Pharmaceuticals, Inc. expanded its collaboration with AstraZeneca, granting rights for AstraZeneca to market eplontersen in countries outside the U.S.
  • In June 2023, Alloy Therapeutics introduced the AntiClastic Antisense Oligonucleotide platform for genetic medicine development.

Report Details

                                    Report Characteristics
Market Size (2024) USD 5.5 Bn
Forecast Value (2033) USD 27.2 Bn
CAGR (2023-2032) 19.4%
Historical Data 2018 – 2023
Forecast Data 2024 – 2033
Base Year 2023
Estimate Year 2024
Report Coverage Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc.
Segments Covered By Technology (RNA Interference, Antisense RNA), By Route of Administration (Intrathecal Injections, Intravenous Injections, Subcutaneous Injections, Others), By Application (Neurodegenerative Disorders, Genetic Disease, Cancer, Infectious Disease, Cardiometabolic & Renal Disorders, Others)
Regional Coverage North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
Prominent Players GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Sarepta Therapeutics, Percheron Therapeutics Limited, Others
Purchase Options We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively.

 

Frequently Asked Questions

  • How big is the Global Antisense and RNAi Therapeutics Market?

    The Global Antisense and RNAi Therapeutics Market size is estimated to have a value of USD 5.5 billion in 2024 and is expected to reach USD 27.2 billion by the end of 2033.

  • Which region accounted for the largest Global Antisense and RNAi Therapeutics Market?

    North America has the largest market share for the Global Antisense and RNAi Therapeutics Market with a share of about 66.2% in 2024.

  • Who are the key players in the Global Antisense and RNAi Therapeutics Market?

    Some of the major key players in the Global Antisense and RNAi Therapeutics Market are Olix Pharmaceuticals, Inc. GSK plc., Sanofi, Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, and many others.

  • What is the growth rate in the Global Antisense and RNAi Therapeutics Market?

    The market is growing at a CAGR of 19.4 percent over the forecasted period.

  • Contents

      1.Introduction
        1.1.Objectives of the Study
        1.2.Market Scope
        1.3.Market Definition and Scope
      2.Antisense and RNAi Therapeutics Market Overview
        2.1.Global Antisense and RNAi Therapeutics Market Overview by Type
        2.2.Global Antisense and RNAi Therapeutics Market Overview by Application
      3.Antisense and RNAi Therapeutics Market Dynamics, Opportunity, Regulations, and Trends Analysis
        3.1.Market Dynamics
          3.1.1.Antisense and RNAi Therapeutics Market Drivers
          3.1.2.Antisense and RNAi Therapeutics Market Opportunities
          3.1.3.Antisense and RNAi Therapeutics Market Restraints
          3.1.4.Antisense and RNAi Therapeutics Market Challenges
        3.2.Emerging Trend/Technology
        3.3.PESTLE Analysis
        3.4.PORTER'S Five Forces Analysis
        3.5.Technology Roadmap
        3.6.Opportunity Map Analysis
        3.7.Case Studies
        3.8.Opportunity Orbits
        3.9.Pricing Analysis
        3.10.Ecosystem Analysis
        3.11.Supply/Value Chain Analysis
        3.12.Covid-19 & Recession Impact Analysis
        3.13.Product/Brand Comparison
      4.Global Antisense and RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Technology, 2017-2032
        4.1.Global Antisense and RNAi Therapeutics Market Analysis by By Technology: Introduction
        4.2.Market Size and Forecast by Region
        4.3.RNA Interference
        4.4.Antisense RNA
      5.Global Antisense and RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Route of Administration, 2017-2032
        5.1.Global Antisense and RNAi Therapeutics Market Analysis by By Route of Administration: Introduction
        5.2.Market Size and Forecast by Region
        5.3.Intrathecal Injections
        5.4.Intravenous Injections
        5.5.Subcutaneous Injections
        5.6.Others
      6.Global Antisense and RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Application, 2017-2032
        6.1.Global Antisense and RNAi Therapeutics Market Analysis by By Application: Introduction
        6.2.Market Size and Forecast by Region
        6.3.Neurodegenerative Disorders
        6.4.Genetic Disease
        6.5.Cancer
        6.6.Infectious Disease
        6.7.Cardiometabolic & Renal Disorders
        6.8.Others
      10.Global Antisense and RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2017-2032
        10.1.North America
          10.1.1.North America Antisense and RNAi Therapeutics Market: Regional Analysis, 2017-2032
            10.1.1.1.The US
            10.1.1.2.Canada
        10.2.1.Europe
          10.2.1.Europe Antisense and RNAi Therapeutics Market: Regional Trend Analysis
            10.2.1.1.Germany
            10.2.1.2.France
            10.2.1.3.UK
            10.2.1.4.Russia
            10.2.1.5.Italy
            10.2.1.6.Spain
            10.2.1.7.Nordic
            10.2.1.8.Benelux
            10.2.1.9.Rest of Europe
        10.3.Asia-Pacific
          10.3.1.Asia-Pacific Antisense and RNAi Therapeutics Market: Regional Analysis, 2017-2032
            10.3.1.1.China
            10.3.1.2.Japan
            10.3.1.3.South Korea
            10.3.1.4.India
            10.3.1.5.ANZ
            10.3.1.6.ASEAN
            10.3.1.7.Rest of Asia-Pacifc
        10.4.Latin America
          10.4.1.Latin America Antisense and RNAi Therapeutics Market: Regional Analysis, 2017-2032
            10.4.1.1.Brazil
            10.4.1.2.Mexico
            10.4.1.3.Argentina
            10.4.1.4.Colombia
            10.4.1.5.Rest of Latin America
        10.5.Middle East and Africa
          10.5.1.Middle East and Africa Antisense and RNAi Therapeutics Market: Regional Analysis, 2017-2032
            10.5.1.1.Saudi Arabia
            10.5.1.2.UAE
            10.5.1.3.South Africa
            10.5.1.4.Israel
            10.5.1.5.Egypt
            10.5.1.6.Turkey
            10.5.1.7.Rest of MEA
      11.Global Antisense and RNAi Therapeutics Market Company Evaluation Matrix, Competitive Landscape, Market Share Analysis, and Company Profiles
        11.1.Market Share Analysis
        11.2.Company Profiles
          11.3.1.Company Overview
          11.3.2.Financial Highlights
          11.3.3.Product Portfolio
          11.3.4.SWOT Analysis
          11.3.5.Key Strategies and Developments
        11.4.GSK plc
          11.4.1.Company Overview
          11.4.2.Financial Highlights
          11.4.3.Product Portfolio
          11.4.4.SWOT Analysis
          11.4.5.Key Strategies and Developments
        11.5.Olix Pharmaceuticals, Inc.
          11.5.1.Company Overview
          11.5.2.Financial Highlights
          11.5.3.Product Portfolio
          11.5.4.SWOT Analysis
          11.5.5.Key Strategies and Developments
        11.6.Sanofi
          11.6.1.Company Overview
          11.6.2.Financial Highlights
          11.6.3.Product Portfolio
          11.6.4.SWOT Analysis
          11.6.5.Key Strategies and Developments
        11.7.Alnylam Pharmaceuticals, Inc.
          11.7.1.Company Overview
          11.7.2.Financial Highlights
          11.7.3.Product Portfolio
          11.7.4.SWOT Analysis
          11.7.5.Key Strategies and Developments
        11.8.Arbutus Biopharma
          11.8.1.Company Overview
          11.8.2.Financial Highlights
          11.8.3.Product Portfolio
          11.8.4.SWOT Analysis
          11.8.5.Key Strategies and Developments
        11.9.Benitec Biopharma Inc.
          11.9.1.Company Overview
          11.9.2.Financial Highlights
          11.9.3.Product Portfolio
          11.9.4.SWOT Analysis
          11.9.5.Key Strategies and Developments
        11.10.Silence Therapeutics
          11.10.1.Company Overview
          11.10.2.Financial Highlights
          11.10.3.Product Portfolio
          11.10.4.SWOT Analysis
          11.10.5.Key Strategies and Developments
        11.11.Ionis Pharmaceuticals, Inc
          11.11.1.Company Overview
          11.11.2.Financial Highlights
          11.11.3.Product Portfolio
          11.11.4.SWOT Analysis
          11.11.5.Key Strategies and Developments
        11.12.Sarepta Therapeutics
          11.12.1.Company Overview
          11.12.2.Financial Highlights
          11.12.3.Product Portfolio
          11.12.4.SWOT Analysis
          11.12.5.Key Strategies and Developments
        11.13.Percheron Therapeutics Limited
          11.13.1.Company Overview
          11.13.2.Financial Highlights
          11.13.3.Product Portfolio
          11.13.4.SWOT Analysis
          11.13.5.Key Strategies and Developments
        11.14.Others
          11.14.1.Company Overview
          11.14.2.Financial Highlights
          11.14.3.Product Portfolio
          11.14.4.SWOT Analysis
          11.14.5.Key Strategies and Developments
      12.Assumptions and Acronyms
      13.Research Methodology
      14.Contact
    If your country is missing in the list, we apologize that we still do not serve in your country.

    Your personal details are safe and secured with us.

    If your country is missing in the list, we apologize that we still do not serve in your country.

    Your personal details are safe and secured with us.

    Select License Type


    • RC-793

    • March-2024
      • ★★★★★
        ★★★★★
      • 73
    • $3190
    • $4590
    • $5690
    Download Free Brochure Customization Request Buy Country Level Reports Request Discount
    Chat on WhatsApp

    Get in Touch with Us

      USA Flag
    • UNITED STATES
      Phone: +1 732 369 9777
      India Flag
    • India
      Phone: +91 882 677 4855

    Recent Report

    • Compression Therapy Market
    • Pharma Quality Assurance Services Market
    • Pharmaceutical Drug Delivery Market
    • Cellulose Insulation Market
    • Remote Patient Monitoring Market
    • Molecular Diagnostics Market
    • Dental Consumables Market
    • Radioimmunoassay Market
    • Home Healthcare Services Market
    • Varicose Vein Treatment Market
    Secured Payment Options
      /images/payment.png
    Legal
    • Privacy Policy
    • Refund Policy
    • Frequently Asked Questions
    • Terms and Conditions
    Explore Company
    • About Us
    • Contact Us
    • Trending Reports
    • Latest Reports
    • All Industries
    • How to Order
    Contact Detail
    • 957 Route 33, Suite 12 #308
            Hamilton Square, NJ-08690 USA
    • +1 (123) 456 4562 (International)
    • +1 (609) 857 6083 (International)
    • +91 882 677 4855 (Asia)
    • sales@dimensionmarketresearch.com
    Copyright Market Research. ©2025 All rights reserved